Massimo Group to Unveil New Warrior 1500 UTV at Equip Exposition and Showcase Next-Generation Product Platform at 2026 SEMA Show

Xencor, Inc. (XNCR) selected 400 mcg/kg IV as the proposed Phase 3 dose for XmAb819 after Phase 1 data showed 45.5% confirmed ORR and 82% 6-month PFS in ccRCC. A randomized trial vs tivozanib is planned, with potential registration-enabling study by end of 2027.

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data for pumitamig plus docetaxel in metastatic non-small cell lung cancer. The trial showed a 36.7% objective response rate and 90.0% disease control rate. Median progression-free survival was 6.9 months. Adverse events were reported in 52.0% of patients, with 18.0% grade 3 or higher. Data were presented at the European Society for Medical Oncology Congress 2026.

Eli Lilly presented data at ESMO 2026 showing promising results for olomorasib, an investigational treatment for KRAS G12C-mutant non-small cell lung cancer (NSCLC). The data showed durable efficacy in combination with immunotherapy, with or without chemotherapy, across PD-L1 expression levels. Olomorasib is not yet approved but has received Breakthrough Therapy designation from the FDA. The ongoing Phase 3 SUNRAY-01 study is evaluating olomorasib in first-line KRAS G12C-mutant NSCLC.

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data for pumitamig plus docetaxel in advanced NSCLC. The combination showed a 36.7% objective response rate and 6.9-month median progression-free survival. The trial involved 50 patients, with responses observed across PD-L1 levels and histologies. The companies are advancing pumitamig in multiple lung cancer trials.

Innovent Biologics (HKEX: 01801) presented Phase 1 data for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC, at the 2026 ESMO Congress. The study showed manageable safety and encouraging efficacy across multiple solid tumors, including NSCLC, pancreatic cancer, and SCLC. The overall ORR was 30.2%, and the DCR was 88.7%. IBI3001 is advancing to Phase 1b dose-optimization studies.

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced death risk by 58% in extensive-stage small cell lung cancer patients, per phase 3 trial results. Median overall survival was 21.1 months vs. 12.7 months for Imfinzi alone. The combination also extended progression-free survival but had higher side effects. Results were presented at ESMO 2026 and published in NEJM.